Latest Next Science (Asx:Nxs) News

Next Science Limited has applied for voluntary delisting from the ASX following the sale of nearly all its assets to OSARTIS GmbH. The company proposes a capital return to shareholders and intends to commence winding up after delisting.

Next Science has obtained a crucial ASX waiver allowing it to return surplus capital to shareholders following its $50 million asset sale, despite expected share price declines below 20 cents.

Next Science reported a 3% rise in Q3 product sales and completed a $50 million asset sale to OSARTIS GmbH, setting the stage for a significant shareholder return.

Next Science has finalised the sale of nearly all its assets to OSARTIS GmbH for US$50 million, with plans to return approximately US$30 million net proceeds to shareholders following legal and tax review.

Next Science reports a 42% improvement in adjusted EBITDA loss for 1H FY25 despite a 7% dip in product sales, while shareholders approve a major asset sale to OSARTIS GmbH.

Next Science Limited reported a 7% revenue decline and a 20% reduction in net loss for H1 2025, alongside a major $50 million asset sale agreement with OSARTIS GmbH. The transaction, approved by shareholders, signals a strategic pivot for the biofilm-focused medical device company.

Next Science reports a 10% decline in quarterly product sales but advances a $50 million asset sale to Demetra Holdings, signaling a pivotal shift in its business strategy.

Next Science Limited has agreed to sell most of its assets to Demetra Holdings for US$50 million, with plans to return an estimated US$30 million net proceeds to shareholders pending approval.

Next Science Limited has successfully had a derivative complaint dismissed in Florida, while continuing legal action against former employees for breach of post-employment restraints.

Next Science reported a 2.9% revenue increase to US$22.8 million in FY24, driven by an 85% surge in XPERIENCE™ sales, while achieving adjusted EBITDA and cashflow positivity in 4Q FY24 amid strategic cost restructuring.